Sekhar upbeat on Stride Arcolab, Subros

Sekhar told CNBC TV18, “The space that suffers least from visibility is the midcap pharma space. There are stocks such as a Strides Arcolabs that we like. In auto ancillaries we believe, although there has some kind of growth problems at least on the bottom line front, the top line is growing well. I think that is a space where we like some of the tyre stocks and stories like Subros, which have been beaten out of shape. There is a lot of value out there.”

He further added, “In capital goods space, we might be 6 months early into the game, but stories such as Blue Star or a Voltas excite us. So these are some of the spaces that we are trying to play. Although I would like to hear candidly admit that we might be 6 months early into the game, but since nobody can time, we are trying to accumulate that.”